Suomen Terveystalo Oy

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions

• Narcolepsy5 trials
• Depression3 trials
• Migraine3 trials
• COPD2 trials
• Alzheimer disease1 trial
• Atopic dermatitis (eczema)1 trial
• Bipolar disorder1 trial
• Coeliac disease1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Insomnia1 trial
• Obesity1 trial
• and 1 more

Phase

• Phase 312 trials
• Phase 22 trials
• Phase 42 trials
• Early phase 11 trial
• Phase 11 trial
• Phase 2/31 trial

Status

• Completed8 trials
• Recruiting5 trials
• Active, not recruiting3 trials
• Suspended2 trials
• Not yet recruiting1 trial

Lead sponsor

• Alkermes Inc.2 trials
• Amgen Inc.2 trials
• AstraZeneca2 trials
• Pfizer2 trials
• Takeda2 trials
• and 8 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-524711-36-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-523911-13-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  NCT06976203· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

  NCT07613710· Phase 1· H. Lundbeck A/S· Source

• Active, not recruiting

  A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

  NCT06807463· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

  NCT05816382· Phase 2/3· Takeda· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Narcolepsy3 recruiting
• Alzheimer disease1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Janssen Cilag International· Source

• Completed

  A Study of TAK-861 in People With Narcolepsy Type 1

  NCT06505031· Phase 3· Takeda· Source

• Completed

  Efficacy and Tolerability of Tasipimidine in Sleepless Patients

  NCT06956495· Phase 2· Orion Corporation, Orion Pharma· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Amgen Inc.· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

  NCT05518123· Phase 4· Pfizer· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

  NCT05509400· Phase 4· Pfizer· Source

• Completed

  A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

  NCT04530110· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source